Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Colao

Showing results (311-320 of 391) with videos related to

Pageof 40
Sort By:
Journal of Endocrinological Investigation|April 1, 2004
Adrenal adenoma and normal androgen levels in a young woman with polycystic ovaries: a case of idiopathic hirsutism?F Orio, S Palomba, T Cascella, et al.
Endocrine-Related Cancer|November 14, 2008
Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancerA Faggiano, F Grimaldi, L Pezzullo, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 23, 2013
Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastasesF Milone, C Pivonello, F Cariati, et al.
The Journal of Clinical Endocrinology and Metabolism|November 4, 2000
Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injectionsG Amato, G Mazziotti, C Di Somma, et al.
The Journal of Clinical Endocrinology and Metabolism|November 30, 2000
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)R Baldelli, A Colao, P Razzore, et al.
Journal of Endocrinological Investigation|July 16, 2011
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard dosesP Ferolla, A Faggiano, F Grimaldi, et al.
The Journal of Clinical Endocrinology and Metabolism|August 24, 2006
Endocrine dysfunction in patients with Fabry diseaseA Faggiano, A Pisani, F Milone, et al.
Clinical Endocrinology|September 1, 1999
Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective studyP Razzore, A Colao, R Baldelli, et al.
Journal of Endocrinological Investigation|November 13, 2007
Ankle brachial pressure index usefulness as predictor factor for coronary heart disease in diabetic patientsM Filippella, E Lillaz, A Ciccarelli, et al.
Clinical Endocrinology|January 29, 2008
Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodiesA De Bellis, A Colao, A Savoia, et al.
Pageof 40

Showing results (311-320 of 391) with videos related to

Sort By:
Pageof 40
Journal of Endocrinological Investigation|April 1, 2004
Adrenal adenoma and normal androgen levels in a young woman with polycystic ovaries: a case of idiopathic hirsutism?F Orio, S Palomba, T Cascella, et al.
Endocrine-Related Cancer|November 14, 2008
Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancerA Faggiano, F Grimaldi, L Pezzullo, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 23, 2013
Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastasesF Milone, C Pivonello, F Cariati, et al.
The Journal of Clinical Endocrinology and Metabolism|November 4, 2000
Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injectionsG Amato, G Mazziotti, C Di Somma, et al.
The Journal of Clinical Endocrinology and Metabolism|November 30, 2000
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)R Baldelli, A Colao, P Razzore, et al.
Journal of Endocrinological Investigation|July 16, 2011
Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard dosesP Ferolla, A Faggiano, F Grimaldi, et al.
The Journal of Clinical Endocrinology and Metabolism|August 24, 2006
Endocrine dysfunction in patients with Fabry diseaseA Faggiano, A Pisani, F Milone, et al.
Clinical Endocrinology|September 1, 1999
Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective studyP Razzore, A Colao, R Baldelli, et al.
Journal of Endocrinological Investigation|November 13, 2007
Ankle brachial pressure index usefulness as predictor factor for coronary heart disease in diabetic patientsM Filippella, E Lillaz, A Ciccarelli, et al.
Clinical Endocrinology|January 29, 2008
Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodiesA De Bellis, A Colao, A Savoia, et al.
Pageof 40